 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...189190191192193194195196197198199...235236» |
- | 5-fluorouracil / Generic mfg.
Enrollment open, Enrollment change, Trial primary completion date, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Jul 11, 2017
P1, N=20, Recruiting, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Recruiting | N=12 --> 20 | Trial primary completion date: May 2017 --> Sep 2017
- | leucovorin calcium / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Jul 7, 2017
P1, N=18, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting | N=12 --> 20 | Trial primary completion date: May 2017 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2018
- | Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 6, 2017
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Jun 2017 --> Jun 2018
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. (Pubmed Central) - Jul 5, 2017
This regimen is safe, with the best 2-year OS and PFS achieved in any Radiation Therapy Oncology Group primary CNS lymphoma trial. Randomized trials that incorporate this regimen are needed to determine its efficacy compared with other strategies.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. (Pubmed Central) - Jul 5, 2017
SC-RT and sequential mFOLFOX6 as preoperative therapy for rectal cancer results in stable patient-reported QOL outcomes 1 year after treatment. These findings in conjunction with previously reported oncologic outcomes support further evaluation of this regimen in a phase 3 setting.
- ||||| Bavencio (avelumab) / EMD Serono
Enrollment change, Metastases: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) (clinicaltrials.gov) - Jul 5, 2017
P3, N=466, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
These findings in conjunction with previously reported oncologic outcomes support further evaluation of this regimen in a phase 3 setting. N=666 --> 466
- | Trial initiation date: Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation (clinicaltrials.gov) - Jul 2, 2017
P2, N=300, Not yet recruiting, Sponsor: Zhejiang University
N=666 --> 466 Initiation date: Mar 2017 --> Nov 2017
- | Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
New P3 trial, Metastases: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 2, 2017
P3, N=512, Not yet recruiting, Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
- || AZD0156 / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 29, 2017
P1, N=225, Recruiting, Sponsor: AstraZeneca
Initiation date: Mar 2017 --> Nov 2017 Trial primary completion date: Mar 2020 --> Jun 2020
- || Ukoniq (umbralisib) / TG Therap
Enrollment closed, Trial primary completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jun 29, 2017
P1, N=65, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Mar 2020 --> Jun 2020 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Nov 2017
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P1/2 trial, PD(L)-1 Biomarker, Metastases: MEDITREME: Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (clinicaltrials.gov) - Jun 29, 2017
P1/2, N=48, Not yet recruiting, Sponsor: Centre Georges Francois Leclerc
- Avastin (bevacizumab) / Roche
New P1 trial, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Jun 29, 2017
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- | Avastin (bevacizumab) / Roche
Trial primary completion date: BEV-ONCO: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. (clinicaltrials.gov) - Jun 28, 2017
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Nov 2017 Trial primary completion date: May 2017 --> May 2019
- | Biomarker, Trial primary completion date, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Jun 28, 2017
P2/3, N=90, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Trial primary completion date: May 2017 --> May 2019 Trial primary completion date: Dec 2016 --> Jun 2018
- futuximab/modotuximab (S95026) / Servier
Trial primary completion date, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jun 26, 2017
P1b/2a, N=10, Active, not recruiting, Sponsor: Symphogen A/S
Trial primary completion date: Dec 2016 --> Jun 2018 Trial primary completion date: May 2018 --> Jun 2017
- | capecitabine / Generic mfg.
Journal: Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. (Pubmed Central) - Jun 25, 2017
P1
The successful completion of this collaborative study demonstrates the feasibility of conducting quality-controlled trials for this disease stage in the multi-institutional setting. The data generated by this study and the logistical elements that facilitated the trial's completion are currently being used to develop cooperative group trials with the goal of improving outcomes for this subset of patients.
- ||||| New P1/2 trial: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- | Enrollment closed, Trial primary completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 22, 2017
P2, N=44, Active, not recruiting, Sponsor: University of Florida
The data generated by this study and the logistical elements that facilitated the trial's completion are currently being used to develop cooperative group trials with the goal of improving outcomes for this subset of patients. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- | Enrollment open, Metastases: Induction Chemotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jun 22, 2017
P2, N=40, Recruiting, Sponsor: University of Rochester
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (clinicaltrials.gov) - Jun 21, 2017
P2/3, N=252, Recruiting, Sponsor: Centre Georges Francois Leclerc
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Initiation date: Mar 2011 --> Jun 2011 | Trial primary completion date: Oct 2016 --> May 2019
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jun 21, 2017
P1, N=588, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting | Initiation date: Mar 2011 --> Jun 2011 | Trial primary completion date: Oct 2016 --> May 2019 Active, not recruiting --> Recruiting | N=142 --> 588
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: XHZL: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 20, 2017
P2, N=50, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- | Oncaspar liquid (pegaspargase) / Servier
Clinical: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Jun 20, 2017
P1, N=116, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | N=142 --> 588 Phase classification: P=N/A --> P1
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. (clinicaltrials.gov) - Jun 20, 2017
P3, N=290, Recruiting, Sponsor: Sun Yat-sen University
- | New P3 trial: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. (clinicaltrials.gov) - Jun 20, 2017
P3, N=162, Recruiting, Sponsor: Sun Yat-sen University
- ||||| New P1/2 trial: MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - Jun 20, 2017
P1/2, N=185, Recruiting, Sponsor: Hoffmann-La Roche
- |||| Herceptin (trastuzumab) / Roche
Trial completion, Trial primary completion date: HerFLOT: Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Jun 19, 2017
P2, N=53, Completed, Sponsor: AIO-Studien-gGmbH
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2014
- | NN1213 / Novo Nordisk
Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 16, 2017
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2014 Trial primary completion date: Dec 2016 --> Dec 2017
- ||||| Vectibix (panitumumab) / Amgen
Enrollment closed: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Jun 16, 2017
P3, N=823, Active, not recruiting, Sponsor: Takeda
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- ||||| Vectibix (panitumumab) / Amgen
Biomarker, Enrollment closed: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Jun 16, 2017
P3, N=766, Active, not recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | PF-04136309 / Pfizer
Journal: Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. (Pubmed Central) - Jun 15, 2017
P1
Recruiting --> Active, not recruiting CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable.
- | Oncaspar liquid (pegaspargase) / Servier
Clinical: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Jun 14, 2017
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable. Trial primary completion date: Jun 2015 --> Aug 2014
- |||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 14, 2017
P2, N=77, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2015 --> Aug 2014 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> May 2014
- ||| Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=719, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> May 2014 Active, not recruiting --> Completed
- | Bavencio (avelumab) / EMD Serono
New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker: SAMCO: Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (clinicaltrials.gov) - Jun 14, 2017
P2, N=118, Not yet recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Be TRI: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Jun 9, 2017
P2, N=65, Completed, Sponsor: EPS Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Jun 8, 2017
P3, N=800, Recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Feb 2020
- ||||| andecaliximab (GS-5745) / Gilead
Enrollment closed, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jun 8, 2017
P3, N=432, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Apr 2017 --> Feb 2020 Recruiting --> Active, not recruiting
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer (clinicaltrials.gov) - Jun 7, 2017
P2, N=180, Active, not recruiting, Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| telisotuzumab (h224G11) / AbbVie
Trial completion, Enrollment change, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 7, 2017
P1, N=74, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=124 --> 74
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open, Trial initiation date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 7, 2017
P2, N=56, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=124 --> 74 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Jun 2017
- ||| IMM-101 / Immodulon
Enrollment closed: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - Jun 7, 2017
P1/2, N=300, Active, not recruiting, Sponsor: Immodulon Therapeutics Ltd
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial initiation date, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Jun 7, 2017
P2/3, N=40, Not yet recruiting, Sponsor: Aslan Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Jun 2017 --> Sep 2017
- | Journal: FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. (Pubmed Central) - Jun 7, 2017
Patients with locally advanced pancreatic cancer treated with FOLFIRINOX had a median overall survival of 24·2 months-longer than that reported with gemcitabine (6-13 months). Future research should assess these promising results in a randomised controlled trial, and should establish which patients might benefit from radiotherapy or chemoradiotherapy or resection after FOLFIRINOX.
- | imalumab (BAX069) / Takeda, Vectibix (panitumumab) / Amgen
Trial termination: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 5, 2017
P2a, N=112, Terminated, Sponsor: Baxalta US Inc.
Future research should assess these promising results in a randomised controlled trial, and should establish which patients might benefit from radiotherapy or chemoradiotherapy or resection after FOLFIRINOX. Active, not recruiting --> Terminated; Based on overall benefit-risk assessment.
- ||||| New P1/2 trial: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Jun 5, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantCell, Inc.
- ||| spartalizumab (PDR001) / Novartis
New P1 trial, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Jun 5, 2017
P1, N=92, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Jun 2, 2017
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Terminated; Based on overall benefit-risk assessment. Trial primary completion date: May 2017 --> May 2018
- || Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, Metastases: AMALTHEA: Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jun 2, 2017
P2, N=73, Active, not recruiting, Sponsor: Hellenic Cooperative Oncology Group
Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: May 2017 --> Jan 2017